Status
Conditions
Treatments
About
The purpose of this study is to help Veterans who have opioid use problems with gaining and maintaining meaningful employment. The investigators also want to know employment helps with other aspects of the Veteran's life including starting and staying on necessary medications, mental health needs, and feeling a part of society.
Full description
The primary aim of this study is to evaluate the employment outcomes of Individual Placement and Support (IPS) compared to Treatment-as-Usual Vocational Rehabilitation (TAU-VR) in 120 Veterans who are recovering from opioid use disorder (OUD) over 15 months. Specifically, the investigators will see which treatment yields more weeks worked in a competitive job with the hypothesis that IPS will result in better outcomes than TAU-VR. The investigators will interview Veterans in both IPS and TAU-VR groups to investigate the contextual barriers and facilitators of implementing vocational services among Veterans with OUD with the aim to provide solutions and leverage facilitators of success as the VHA expands supported employment services to a new priority population. Investigators will evaluate the impact of vocational services on adherence to prescribed treatment and OUD relapse rates. This study is especially timely given the societal impact of the COVID-19 pandemic on employment and occupational functioning.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
current diagnosis of psychotic disorders since these Veterans already can receive IPS in usual care at TVAMC and BVAMC
diagnosis of dementia (evidenced in the medical record)
presence of current severe and unstable medical condition or terminal illness, that would contraindicate study participation or expose them to an undue risk
unlikely that participant can complete the study
active suicidal or homicidal ideation making it unsafe for Veteran to be included
current participation in another vocational interventional trial
Primary purpose
Allocation
Interventional model
Masking
120 participants in 2 patient groups
Loading...
Central trial contact
Lori L Davis, MD AB; Mercy N Mumba, RN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal